Based on the diagnostic criteria
developed in 1999 by the World Health Organization, China has the largest
prevalent population of type 2 diabetes in the world. Combined with increasing
access to medical care and a burgeoning middle class that has newly acquired
economic clout, this large prevalent population promises double-digit pharmaceutical
sales growth and significant opportunity for multinational pharmaceutical
companies as demand for Western-branded antidiabetic drugs continues to grow
Primary research: 90 physician surveys in Beijing, Shanghai, and Guangzhou. Separate in-depth interviews with 8 medical experts.
Epidemiology: Prevalence of type 2 diabetes in urban and rural China. Ten-year epidemiology forecast (2012-2022).
Market forecast features: Our analysis evaluates the size of the patient population, percentage of diagnosed patients, and percentage of drug-treated patients. We include a detailed forecast for antidiabetic drug classes and leading products over 2012-2017 using a combination of historical trend analysis and an epidemiology-based bottom-up market model.